drugset
drugset / Trial / NCT02418559

A Study to Investigate Safety, Tolerability, and Pharmacokinetics of JNJ-63623872 in Healthy Japanese Adult Participants

NCT02418559 ↗

Phase 1 Completed 24 enrolled Janssen Infectious Diseases BVBA
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of JNJ-63623872 following oral administration of single ascending dose of JNJ-63623872 in healthy Japanese adult participants.

Timeline

Start
2015-05
Primary completion
2015-07
Completion
2015-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Pimodivir Small molecule 300 mg Oral
Subject Pimodivir Small molecule 600 mg Oral
Subject Pimodivir Small molecule 1200 mg Oral

Indications

No indication recorded.